309 related articles for article (PubMed ID: 25687872)
1. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
[TBL] [Abstract][Full Text] [Related]
2. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
[TBL] [Abstract][Full Text] [Related]
6. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
[TBL] [Abstract][Full Text] [Related]
8. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
10. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
[TBL] [Abstract][Full Text] [Related]
12. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
Hasanovic A; Ang D; Moreira AL; Zakowski MF
Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
[TBL] [Abstract][Full Text] [Related]
13. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between EGFR Mutations and Pathological Classification and
Specimen of Lung Adenocarcinoma].
Kang L; Zheng J; Zhu X
Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
Ping W; Xia C; Fu S; Cai Y; Deng Y; Sun W; Dong C; Fu X
Tumour Biol; 2015 Feb; 36(2):693-700. PubMed ID: 25286755
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma.
Wang L; Zhang Z; Huang L; Li W; Lu Q; Wen M; Guo T; Fan J; Wang X; Zhang X; Fang J; Yan X; Ni Y; Li X
Analyst; 2014 Jan; 139(2):455-63. PubMed ID: 24303521
[TBL] [Abstract][Full Text] [Related]
20. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
